CASI Pharmaceuticals, Inc. (CASIF)
OTCMKTS · Delayed Price · Currency is USD
0.1350
-0.0310 (-18.67%)
At close: Jul 20, 2026
CASI Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 20.71 | 28.54 | 33.88 | 43.11 | 30.17 | |
Revenue Growth (YoY) | -27.42% | -15.77% | -21.41% | 42.89% | 99.25% |
Cost of Revenue | 10.64 | 17.39 | 13.83 | 15.83 | -12.56 |
Gross Profit | 10.08 | 11.15 | 20.05 | 27.28 | 17.61 |
Selling, General & Admin | 46.61 | 41.44 | 41.84 | 37.78 | -38.47 |
Research & Development | 6.31 | 8.92 | 9.86 | 16 | -7.87 |
Other Operating Expenses | 2.16 | 0.89 | -6.57 | 10.78 | - |
Total Operating Expenses | 55.08 | 51.25 | 45.13 | 64.55 | -46.34 |
Operating Income | -45.01 | -39.62 | -25.08 | -34.03 | -41.84 |
Interest Income | 0.14 | 0.54 | 0.63 | 0.19 | - |
Interest Expense | -0.84 | -0.87 | -0.02 | -0.06 | - |
Other Non-Operating Income (Expense) | -0.16 | 1.88 | -1.83 | -0.29 | 6 |
Total Non-Operating Income (Expense) | -0.86 | 1.55 | -1.21 | -0.16 | 6 |
Pretax Income | -45.87 | -38.07 | -26.29 | -37.43 | -35.84 |
Provision for Income Taxes | - | - | -0.08 | 1.98 | - |
Net Income | -48.06 | -39.26 | -26.26 | -40.26 | -35.84 |
Minority Interest in Earnings | -2.19 | -1.19 | -2.65 | -9.59 | -0.7 |
Net Income Attributable to Preferred Dividends | - | - | 3.3 | 9.5 | 1.51 |
Net Income to Common | -48.06 | -39.26 | -26.96 | -41.01 | -36.65 |
Shares Outstanding (Basic) | 19 | 15 | 13 | 14 | 14 |
Shares Outstanding (Diluted) | 19 | 15 | 13 | 14 | 14 |
Shares Change (YoY) | 20.84% | 14.82% | -2.10% | 0.27% | 23.23% |
EPS (Basic) | -2.59 | -2.56 | -2.02 | -3.01 | -2.70 |
EPS (Diluted) | -2.59 | -2.56 | -2.02 | -3.01 | -2.70 |
Free Cash Flow | -20.77 | -29.45 | -20.17 | -26.7 | -35.79 |
Free Cash Flow Per Share | -1.12 | -1.92 | -1.51 | -1.96 | -2.63 |
Gross Margin | 48.65% | 39.06% | 59.19% | 63.28% | 58.38% |
Operating Margin | -217.30% | -138.84% | -74.03% | -78.95% | -138.68% |
Profit Margin | -232.03% | -137.57% | -77.51% | -93.39% | -118.81% |
FCF Margin | -100.28% | -103.19% | -59.54% | -61.94% | -118.63% |
EBITDA | -42.71 | -36.17 | -20.35 | -30.42 | -38.74 |
EBITDA Margin | -206.23% | -126.75% | -60.07% | -70.57% | -128.42% |
EBIT | -45.01 | -39.62 | -25.08 | -34.03 | -41.84 |
EBIT Margin | -217.30% | -138.84% | -74.03% | -78.95% | -138.68% |
Effective Tax Rate | 0.00% | 0.00% | 0.31% | -5.29% | 0.00% |